Contineum Therapeutics, Inc.

Pharmaceutical Preparations

CTNM Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001855175 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$557.55M
23,099,173 shares Covers every share class this company has on file.
Insiders on file
1
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$2.65M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.48%
insider-held value divided by market capitalisation

What Contineum Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2024, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$0
FY2024 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$59.98M
FY2024 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
51
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Contineum Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

People who file insider reports against Contineum Therapeutics, Inc..
Insider Reported role Shares Value Last action
Daniel S Lorrain Other Executive 158,724 $2.65M S Open-market sale Jul 9, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Daniel S Lorrain sold 28,826 Contineum Therapeutics, Inc. (CTNM) shares for $462,369 on Jun 30, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Daniel S Lorrain sold 28,826 Contineum Therapeutics, Inc. (CTNM) shares for $462,369 on Jun 30, 2026
Date Insider Transaction Shares Price Value Filing
Jun 30, 2026 Daniel S Lorrain S Open-market sale 28,826 held after: 139,372 $16.04 $462,369 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 30 rows we hold, 0 are open-market purchases and 22 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Contineum Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jul 9, 2026 Daniel S Lorrain S Open-market sale 25 $16.00 $400 SEC filing ↗
Jul 9, 2026 Daniel S Lorrain M Option exercise or conversion 25 $1.01 $25 SEC filing ↗
Jul 8, 2026 Daniel S Lorrain S Open-market sale 1,015 $16.00 $16.2K SEC filing ↗
Jul 8, 2026 Daniel S Lorrain M Option exercise or conversion 1,015 $1.01 $1.0K SEC filing ↗
Jul 1, 2026 Daniel S Lorrain S Open-market sale 2,501 $16.24 $40.6K SEC filing ↗
Jul 1, 2026 Daniel S Lorrain S Open-market sale 5,852 $15.67 $91.7K SEC filing ↗
Jul 1, 2026 Daniel S Lorrain M Option exercise or conversion 4,183 $1.01 $4.2K SEC filing ↗
Jun 30, 2026 Daniel S Lorrain S Open-market sale 28,826 $16.04 $462.4K SEC filing ↗
Jun 30, 2026 Daniel S Lorrain M Option exercise or conversion 28,826 $1.01 $29.1K SEC filing ↗
Jun 1, 2026 Daniel S Lorrain S Open-market sale 4,170 $13.16 $54.9K SEC filing ↗
May 1, 2026 Daniel S Lorrain S Open-market sale 300 $13.84 $4.2K SEC filing ↗
May 1, 2026 Daniel S Lorrain S Open-market sale 3,870 $13.06 $50.5K SEC filing ↗
Apr 6, 2026 Daniel S Lorrain S Open-market sale 4,170 $13.43 $56.0K SEC filing ↗
Mar 2, 2026 Daniel S Lorrain S Open-market sale 4,170 $15.01 $62.6K SEC filing ↗
Feb 25, 2026 Daniel S Lorrain M Option exercise or conversion 3,824 $1.01 $3.9K SEC filing ↗
Feb 25, 2026 Daniel S Lorrain S Open-market sale 3,824 $16.01 $61.2K SEC filing ↗
Feb 24, 2026 Daniel S Lorrain S Open-market sale 4,300 $16.03 $68.9K SEC filing ↗
Feb 24, 2026 Daniel S Lorrain M Option exercise or conversion 4,300 $1.01 $4.3K SEC filing ↗
Feb 19, 2026 Daniel S Lorrain M Option exercise or conversion 100 $1.01 $101 SEC filing ↗
Feb 19, 2026 Daniel S Lorrain S Open-market sale 100 $16.00 $1.6K SEC filing ↗
Feb 11, 2026 Daniel S Lorrain S Open-market sale 400 $16.00 $6.4K SEC filing ↗
Feb 11, 2026 Daniel S Lorrain M Option exercise or conversion 400 $1.01 $404 SEC filing ↗
Feb 3, 2026 Daniel S Lorrain S Open-market sale 1,170 $15.25 $17.8K SEC filing ↗
Feb 3, 2026 Daniel S Lorrain S Open-market sale 3,000 $14.82 $44.5K SEC filing ↗
Jan 5, 2026 Daniel S Lorrain S Open-market sale 500 $11.13 $5.6K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 11 filers hold a position

Who owns Contineum Therapeutics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 11 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Contineum Therapeutics, Inc.

Funds, trusts and companies that disclose an ownership position in Contineum Therapeutics, Inc..
Owner Reported role Shares Filed
JOHNSON & JOHNSON JNJ TenPercentOwner 1,979,173 joint
Johnson & Johnson Innovation - JJDC, Inc. TenPercentOwner 1,979,173 joint
Versant Side Fund IV, L.P. TenPercentOwner 523,847 joint
Versant Vantage I GP-GP, LLC TenPercentOwner 523,847 joint
Versant Vantage I GP, L.P. TenPercentOwner 523,847 joint
Versant Vantage I, L.P. TenPercentOwner 523,847 joint
Versant Venture Capital IV, L.P. TenPercentOwner 523,847 joint
Versant Venture Capital VI, L.P. TenPercentOwner 523,847 joint
Versant Ventures IV, LLC TenPercentOwner 523,847 joint
Versant Ventures VI GP-GP, LLC TenPercentOwner 523,847 joint
Versant Ventures VI GP, L.P. TenPercentOwner 523,847 joint

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Contineum Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Contineum Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.